Aptar Digital Health and Moffitt Cancer Center have joined forces to initiate a 15-month clinical evaluation for Oleena, a digital therapeutic developed by Aptar for managing symptoms in cancer care. This collaboration aims to assess Oleena's usability, focusing on key indicators like patient satisfaction, engagement, and clinical outcomes such as symptom burden, treatment adherence, and quality of life.
The evaluation will involve head and neck cancer patients undergoing chemoradiation, using Oleena to self-manage their symptoms with personalised clinical recommendations based on their treatment plans. The digital therapeutic facilitates remote monitoring by automatically transferring patient-entered data to a dedicated web portal, enabling healthcare teams to proactively address potential issues.
The partnership underscores the rising significance of digital health in disease management, offering patients decentralised tools for daily disease management outside traditional clinical settings. Moffitt Cancer Center, known for its scientific excellence, views remote symptom monitoring as a crucial aspect for quickly detecting issues and taking proactive measures to prevent symptom escalation.
Aptar Digital Health's Oleena aligns with the broader goal of reducing treatment discontinuation by addressing challenges associated with treatment toxicities and symptom management, ultimately enhancing the overall patient experience.
Click here to read the original news story.